These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 34743087)

  • 1. Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
    Calza L; Legnani G; Fulgaro C; Verucchi G; Bon I; Lazzarotto T; Viale P
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):e30. PubMed ID: 34743087
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration.
    Thompson AB; Wynn BA; O Akerele D; A Rostad C; Anderson EJ; Camacho-Gonzalez AF; Spearman P; Chakraborty R
    AIDS; 2015 Jan; 29(3):390-2. PubMed ID: 25686687
    [No Abstract]   [Full Text] [Related]  

  • 4. Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
    Calza L; Borderi M; Colangeli V; Miani T; Nuti B; Bon I; Lazzarotto T; Viale P
    AIDS; 2022 Jan; 36(1):153-155. PubMed ID: 34873095
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection.
    Lanzafame M; Lattuada E; Gottardo R; Piacentini D; Be G; Razzaboni E; Cattaneo P; Luise D; Vento S
    Int J Antimicrob Agents; 2021 Mar; 57(3):106290. PubMed ID: 33513407
    [No Abstract]   [Full Text] [Related]  

  • 6. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
    Walmsley S; Baumgarten A; Berenguer J; Felizarta F; Florence E; Khuong-Josses MA; Kilby JM; Lutz T; Podzamczer D; Portilla J; Roth N; Wong D; Granier C; Wynne B; Pappa K
    J Acquir Immune Defic Syndr; 2015 Dec; 70(5):515-9. PubMed ID: 26262777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
    Blackman AL; Heil EL; Devanathan AS; Pandit NS
    Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
    Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
    [No Abstract]   [Full Text] [Related]  

  • 9. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
    Jary A; Marcelin AG; Charpentier C; Wirden M; Lê MP; Peytavin G; Descamps D; Calvez V
    J Antimicrob Chemother; 2020 May; 75(5):1290-1293. PubMed ID: 32065630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir.
    Calza L; Bon I; Pensalfine G; Vitale S; Appolloni L; Viale P
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):e9-e11. PubMed ID: 35981265
    [No Abstract]   [Full Text] [Related]  

  • 12. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
    van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine.
    Sun J; Lu H
    Drug Discov Ther; 2021 Sep; 15(4):225-226. PubMed ID: 34334555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
    Letendre SL; Mills AM; Tashima KT; Thomas DA; Min SS; Chen S; Song IH; Piscitelli SC;
    Clin Infect Dis; 2014 Oct; 59(7):1032-7. PubMed ID: 24944232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
    Ciccullo A; Borghi V; Giacomelli A; Cossu MV; Sterrantino G; Latini A; Giacometti A; De Vito A; Gennari W; Madeddu G; Capetti A; d'Ettorre G; Mussini C; Rusconi S; Di Giambenedetto S; Baldin G
    J Acquir Immune Defic Syndr; 2021 Nov; 88(3):234-237. PubMed ID: 34446677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trial.
    Hill AM; Elbirt D
    AIDS; 2024 Jul; 38(9):1430-1431. PubMed ID: 38932745
    [No Abstract]   [Full Text] [Related]  

  • 19. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.
    Gianella S; Marconi VC; Berzins B; Benson CA; Sax P; Fichtenbaum CJ; Wilkin T; Vargas M; Deng Q; Oliveira MF; Moser C; Taiwo BO
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):e112-e114. PubMed ID: 30383591
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.